Proscia Raises $50M To Advance AI-Driven Pathology And Deliver The Future Of Precision Medicine

Proscia is rewiring pathology to speed up the development of targeted therapies, accelerate diagnosis, and match more patients with the best course of treatment

Funding led by global software investor Insight Partners comes as the surge in cancer cases compounds the impact of the shrinking pathologist workforce

The company will use the funds to grow its customer footprint and advance Concentriq, with focus on extending the platform's core AI capabilities

PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Proscia®, a software company leading pathology's transition to digital and AI, has secured $50M in funding, bringing its total raised to $130M. This investment follows Proscia's record-breaking growth in 2024. Proscia now counts 16 of the top 20 pharmaceutical companies among its users and is on track for 22,000+ patients to be diagnosed on its Concentriq® software platform each day.

Cancer patients often wait more than two months to receive a diagnosis and start treatment1 as the rest of medicine races ahead. Pathology—the bedrock of up to 70% of clinical decisions2 and a critical driver of every drug brought to market—is among the last fields of healthcare to modernize, despite mounting pressures from a workforce shortage and rising case volume. Proscia is rewiring pathology, shifting it from microscope to data-rich images, to overcome these challenges, unlock new insights, and shape the future of care.

At the center of this transformation is Proscia's Concentriq, the only AI-driven pathology platform underpinning the precision medicine value chain. In powering drug discovery ...